MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced it will present one-year clinical outcomes from the 2,400 patient INFINITY-SWEDEHEART Randomized Clinical Trial (RCT), a prospective, multi-center, single-blind, clinical trial comparing the drug-eluting DynamX Coronary Bioadaptor System with the contemporary Resolute OnyxTM zotarolimus drug-eluting stent […]
Other News
Radiaction Medical Establishes Medical Advisory Board
TEL AVIV, Israel–(BUSINESS WIRE)–Radiaction Medical, LTD (“Radiaction”), a medical device company, has announced the formation of its U.S. Medical Advisory Board (MAB). The MAB will provide invaluable counsel and expertise to the company’s executive team, bolstering Radiaction’s mission to deliver comprehensive radiation protection to all medical staff involved in interventional […]
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
August 12, 2024 04:01 PM Eastern Daylight Time MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed […]
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™
Rivus Pharmaceuticals’ Phase 2a HuMAIN Trial Meets Primary Endpoint of Weight Loss and Secondary Endpoints in Patients with Obesity-Related Heart Failure
– Data from the HuMAIN study in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) will be presented in a Late Breaking Clinical Trial Plenary Session at the Heart Failure Society of America Annual Scientific Meeting – – Enrollment completed in Phase 2…
Boston Scientific to Participate in Wells Fargo’s 2024 Healthcare Conference
MARLBOROUGH, Mass., Aug. 13, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo’s 2024 Healthcare Conference on Wednesday, September 4, 2024. Mike Mahoney, chairman and chief executive officer, and Dr. Brad Sutton, chief medical officer, Atrial…
Humacyte Second Quarter 2024 Financial Results and Business Update
-FDA requires additional time to complete its review of ATEV™ (acellular tissue engineered vessel) BLA for the Treatment of Vascular Trauma-
SPECTUM DYNAMICS MEDICAL AND DEEPDENSE MEDICAL ENTER INTO A PARTNERSHIP TO REVOLUTIONIZE AI IN CARDIAC AND SPINE DISEASE IMAGING AND TREATMENT
SARASOTA, Fla., Aug. 13, 2024 /PRNewswire/ — Spectrum Dynamics Medical, a leading innovator in digital SPECT-CT imaging solutions, announced that its partnering with DEEPDENSE Medical, developing innovative AI-based clinical applications to revolutionize Cardiac and Spine disease…
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
• Funding supports advancement of oral levosimendan (TNX-103) Phase 3 development program, including completion of the ongoing LEVEL Study for the treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Acarix expands within US wellness exam market
NEW YORK, Aug. 12, 2024 /PRNewswire/ — Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, announces expanded use of the CADScor System within wellness exams as part of self-insured companies’ health plans. As healthcare costs continue to rise, the CADScor System has…
Recent
Efemoral Medical Reports Exceptional Long-Term EFEMORAL I Results Highlighting Durability and Differentiated Performance in Femoropopliteal Disease
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
First Peer-Reviewed Study to Evaluate AI-Generated Impressions Demonstrates Radiologist Preference for Domain-Specific Versus General Models
Popular
- No commented posts yet